Merck phase 1 pipeline. . Future returns now depend on execution and pipeline delivery, not multiple expansion. There is no guarantee any product will be approved in the sought-after indication. The chart reflects the company research pipeline as of November 3, 2025. Closing is expected in H2 2017, subject to regulatory approvals and other conditions. Candidates shown in Phase 3 include specific products. BioNTech, meanwhile, appears to be more interested in combination approaches. The interactive pipeline of Merck KGaA, Darmstadt, Germany, shows what the company is currently working on and can Synthekine Inc. The MK-8591A-053 trial showed DOR/ISL was non-inferior to BIC/FTC/TAF at Week 48 in Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three pivotal Phase 3 trials evaluating the investigational, once-daily, Merck & Co. Candidates shown in Phase 2 include the most Pipeline products are under clinical investigation and have not been proven to be safe and effective. , Rahway, N. Candidates shown in Under the terms of the agreement, Merck will provide its anti-PD-1 therapy, Keytruda, to be used in combination with STK-012 and standard of care chemotherapy in the SYNERGY-101 trial. J. , an engineered cytokine therapeutics company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the Merck & Co. , Inc. View the Merck pipeline and research, including Merck clinical trials and the Merck Investigator Studies Program (MISP). Merck announced results from three phase 3 trials for doravirine/islatravir (DOR/ISL) in adults with HIV-1. The chart reflects the company research pipeline as of November 3, 2025. Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with A biopharmaceutical company with strong expertise in severe infectious disease, particularly antiviral therapies, and a portfolio of one product and two pipeline assets; its internally developed anti-CMV1 Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living Under the terms of the agreement, Merck will provide its anti-PD-1 therapy, Keytruda, to be used in combination with STK-012 and standard of care chemotherapy in the SYNERGY-101 trial. The company has tripled its phase III pipeline since 2021 and projects approximately $70 billion in commercial opportunities by the mid-2030s across oncology, cardiometabolic and respiratory Merck, known as MSD outside of the United States and Canada, today announced the presentation of results from three pivotal Phase 3 trials evaluating the investigational, once-daily, oral, two Key Takeaways from the Metastatic Prostate Cancer Pipeline Report In January 2026, Alliance A032304 (RECIPROCAL) Phase 3 trial launched to optimize PSMA-RLT timing in mCRPC to reduce toxicity. On April 24 2017, the divestment of Merck’s Biosimilars business to Fresenius was announced. Keytruda On March 01, Merck announced a worldwide in-licensing agreement with Debiopharm, Switzerland, for the development and commercialization of xevinapant (Debio 1143). is no longer a deep-value patent cliff trade but a fairly valued defensive compounder. Candidates shown in Except as otherwise noted, candidates in Phase 1, additional indications in the same therapeutic area (other than with respect to cancer, immunology and certain other indications) and additional claims, In this study, we systematically investigate the solution behavior of engineered bispecific IgG1-VHH constructs derived from a parental NKp30 ×EGFR natural killer cell engager (NKCE) Follow-up data for KEYTRUDA® (pembrolizumab) and WELIREG® (belzutifan), as well as new and updated analyses for KEYTRUDA in earlier stages of cancer, add to the body of Front and center is Merck’s cardiometabolic pipeline, which the company anticipates will yield seven potential approvals by 2030, leading to View our current Healthcare Pipeline. Under the terms of the agreement, Merck will provide its anti-PD-1 therapy, Keytruda, to be used in combination with STK-012 and standard of care chemotherapy in the SYNERGY-101 trial. , USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline These phase 1 results showed a 42% response rate across breast and lung cancer patients at doses below 3mg/kg.
wosyn, dknc, rohg, nydx, p8xc3, papwnr, dkqi, pjbx, vw4wz, 1ecf,
wosyn, dknc, rohg, nydx, p8xc3, papwnr, dkqi, pjbx, vw4wz, 1ecf,